Gufic Biosciences Limited (BOM: 509079)

Market Cap	40.09B
Revenue (ttm)	8.14B
Net Income (ttm)	863.69M
Shares Out	100.28M
EPS (ttm)	8.69
PE Ratio	46.01
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 18, 2024

Volume	29,462
Open	400.00
Previous Close	392.15
Day's Range	393.80 - 405.50
52-Week Range	237.90 - 418.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,491
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In 2023, Gufic Biosciences's revenue was 8.07 billion, an increase of 16.80% compared to the previous year's 6.91 billion. Earnings were 861.36 million, an increase of 8.07%.